.png){kind=icon}
.png){kind=icon}
Return
Long-term effectiveness, safety, and cost-effectiveness of intravenous immunoglobulin for generalized myasthenia gravis in an era of molecular targeted drugs: Insights from Japanese post-marketing surveillance
.png){kind=icon}
OA
AI
S
M
T
Y
H
DOI：10.1016/j.jaut.2026.103588.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Intravenous immunoglobulin (IVIg) is widely used for generalized myasthenia gravis (gMG). • This study included 1041 gMG patients with mean MG-ADL score, 9.45. • The median time to retreatment was 386 days in all patients. • The MG-ADL responder rate (≥2-point improvement) of IVIg was 65.7% on day 14. • The cost per MG-ADL improvement for IVIg was lower than that for molecular targeted drugs.
Keywords:
Intravenous immunoglobulin
Generalized myasthenia gravis
Post-marketing surveillance
Cost-effectiveness
Molecular targeted drugs
Myasthenia Gravis Activities of Daily Living
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
7
Papers:
3.1K
Citations:
1.0W
Organization
Cited Papers